Needham Reiterates Buy on Hologic, Maintains $95 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Mike Matson has reiterated a 'Buy' rating on Hologic (NASDAQ:HOLX) and maintained a price target of $95.
August 01, 2023 | 9:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Mike Matson has reiterated a 'Buy' rating on Hologic, maintaining a price target of $95.
The reiteration of a 'Buy' rating by a respected analyst like Mike Matson is a positive signal for Hologic. The maintained price target of $95 indicates that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100